News und Analysen
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and CEO, at the Goldman Sachs 14th Annual Healthcare CEOs
Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, February 8, 2022. The
Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir [PF-07321332] tablets and ritonavir tablets) for
Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Pfizer Inc. (NYSE: PFE) announced an additional agreement with the United Kingdom (UK) government to supply an additional 2.5 million treatment courses of its investigational candidate PAXLOVID™
Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
Pfizer Inc. (NYSE: PFE) announced today the publication of a post-hoc, interim analysis showing that treatment with VYNDAQEL® (tafamidis meglumine) / VYNDAMAX® (tafamidis) provided a clinically
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced an agreement has been reached with the European Commission (EC) and its member states to exercise an option to purchase more
EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
Pfizer Inc. (NYSE: PFE) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued advice on the use of PAXLOVID™ (nirmatrelvir
U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for XELJANZ® / XELJANZ® XR (tofacitinib) for the
Humana and The Humana Foundation Offer Support to Those Affected by Tornados
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, launched a series of efforts to assist its members, employees and communities in the Midwest and southern part
Agilent to Present at Goldman Sachs and J.P. Morgan Healthcare Conferences
Agilent Technologies Inc. (NYSE: A) today announced the company will deliver presentations at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference and the J.P. Morgan 40th Annual
Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Pfizer Inc. (NYSE: PFE) today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients)
Pfizer to Acquire Arena Pharmaceuticals
Pfizer Inc. (NYSE: PFE) and Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the companies have entered into a definitive agreement under which Pfizer will acquire Arena, a clinical
Pfizer Declares First-Quarter 2022 Dividend
Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared an increase in the quarterly cash dividend on the company’s common stock to $0.40 for the first-quarter 2022 dividend
European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved the 100 mg and 200 mg doses of Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor
Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) of a booster dose of the
Humana Military Earns URAC Accreditations in Case and Disease Management
Humana Military, a wholly owned subsidiary of Humana Inc. (NYSE: HUM), announced today that it has earned a three-year Case Management Accreditation and a Disease Management Accreditation from URAC
Pfizer and BioNTech Provide Update on Omicron Variant
Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced results from an initial laboratory study demonstrating that serum antibodies induced by the Pfizer-BioNTech COVID-19 Vaccine
Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live webcast of a presentation and conference call with investment analysts at 8:30 a.m. EST on Friday, December 17
Loudoun Medical Group Joins Humana Medicare Advantage Network
Loudoun Medical Group, P.C. (LMG), one of the largest and most diverse physician-owned, multi-specialty group practices in Virginia, and leading health and well-being company Humana Inc. (NYSE
4 Dividend Aristocrats Trading at a Discount
The first quarter of the year was a success for investors. The overall market (NYSE: SPY) surged nearly 10%, fueled by robust economic indicators, optimism, and hype surrounding AI. The
Pfizer’s earnings growth trade at a deep discount, suddenly a buy
The defensive names, characterized by their immunity to the business cycle, in the market could soon see an inflow of investment dollars not seen since the last wave of the business cycle. This
MarketBeat Week in Review – 5/22 - 5/26
Two competing stories are fighting for investors’ attention. The bulls are trying to push the market higher in expectations of a resolution to the debt ceiling standoff. But any excitement is being
Humana Slides on Profitability Concerns Despite Q2 Earnings Beat
Humana Inc. (NYSE: HUM) is a leading health insurer predominantly focused on Medicare Advantage plans, serving millions of individuals and families nationwide. The company's business model centers
AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
AbbVie (NYSE: ABBV) was among the pharma companies worst positioned for a patent cliff that has come and gone. However, management's lean toward diversifying away from Humira and into a broader
Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
As the second half of the year has gotten underway, the healthcare sector, represented by the XLV ETF, has seen a notable resurgence. This sector, which had been underperforming since the